Sodium Gluconate
FDA-approved product (injectable, injection).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBL- Anti-infective classification
- Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Sodium Gluconate, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA10.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli23.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae11.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis18.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Sodium Gluconate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pitavastatin SodiumExisting use: Abnormal circulating lipid concentration, Cardiovascular disease, Familial hypercholesterolemia and 2 more66.8% AI-predicted activityagainst M. tuberculosis18 registered studies
- AmisulprideExisting use: Nausea and vomiting, Post operative nausea and vomiting, Psychosis66.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ItraconazoleExisting use: Aspergillosis, Blastomycosis, Candidiasis and 4 more66.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Dantrolene SodiumExisting use: Cerebral palsy, Fever, Malignant hyperthermia and 4 more66.6% AI-predicted activityagainst M. tuberculosis12 registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma66.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Methixene HydrochlorideExisting use: Parkinson disease66.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Cisapride MonohydrateExisting use: Gastrointestinal disease66.5% AI-predicted activityagainst M. tuberculosis5 registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more66.3% AI-predicted activityagainst M. tuberculosis10 registered studies
- QuazepamExisting use: Insomnia66.3% AI-predicted activityagainst M. tuberculosis1 registered study
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TerconazoleExisting use: Triazole derivatives66.2% AI-predicted activityagainst M. tuberculosis10 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma66.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Micronutrient Sprinkles in a Daycare Center
NCT00967551 · start 2009-07
Registered record
- Registry ID
- NCT00967551
- Conditions
- Diarrhea; Respiratory Infection
- Interventions
- Micronutrient Sprinkles with zinc; Micronutrient sprinkles without zinc
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-07
- Completion
- 2012-07
- Enrolment
- 143
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiarrhea; Respiratory InfectionInterventionMicronutrient Sprinkles with zinc; Micronutrient sprinkles without zincPhasePhase 3Registry statusCompletedPhase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
NCT01009502 · start 2009-07
Registered record
- Registry ID
- NCT01009502
- Conditions
- Myelodysplastic Syndromes
- Interventions
- sodium stibogluconate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Terminated
- Start
- 2009-07
- Completion
- 2013-05
- Enrolment
- 1
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyelodysplastic SyndromesInterventionsodium stibogluconatePhasePhase 1Registry statusTerminatedCombined Vitamins and Minerals Decrease Incidence of Upper Respiratory Tract Infections in Older Persons
NCT01484756 · start 2008-08
Registered record
- Registry ID
- NCT01484756
- Conditions
- Upper Respiratory Tract Infection
- Interventions
- daily multi micronutrient supplement; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-08
- Completion
- 2009-03
- Enrolment
- 270
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUpper Respiratory Tract InfectionInterventiondaily multi micronutrient supplement; PlaceboPhasePhase 3Registry statusCompletedStudy of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit
NCT00549393 · start 2008-02
Registered record
- Registry ID
- NCT00549393
- Conditions
- Nosocomial Infections
- Interventions
- 2% Chlorhexidine gluconate cloth
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2008-02
- Completion
- 2012-06
- Enrolment
- 5,659
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNosocomial InfectionsIntervention2% Chlorhexidine gluconate clothPhasePhase 2 / Phase 3Registry statusCompletedSerum NGAL Levels in Hemodialysis (HD) Patients; Relation to Iron Status, HD and Intravenous (IV) Iron Administration
NCT00560976 · start 2005-12
Registered record
- Registry ID
- NCT00560976
- Conditions
- Renal Failure Chronic Requiring Hemodialysis
- Interventions
- Iron Saccharate (Venofer)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2005-12
- Completion
- 2014-12
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRenal Failure Chronic Requiring HemodialysisInterventionIron Saccharate (Venofer)PhaseNot applicableRegistry statusUnknown